B. Riley initiated coverage of HeartBeam (BEAT) with a Buy rating and $4 price target HeartBeam is a medical technology company that has developed the first and only FDA-cleared, cable-free device capable of synthesizing a clinical-grade 12-lead electrocardiogram from 3D signal capture, the analyst tells investors in a research note. The firm expects “rapid deployment” of HeartBeam Systems across concierge and preventive cardiology practices. Riley expects positive stock momentum to build with the company’s regulatory updates from expansion over the coming years.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam initiated with a Buy at Stifel
- HeartBeam initiated with a Buy at D. Boral Capital
- HeartBeam (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation
- HeartBeam Earnings Call Balances Breakthroughs With Cash Risk
- HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development